drugset
drugset / Trial / NCT05053893

Roxadustat Combined With Sacubitril Valsartan Sodium Tablets in the Treatment of Cardiorenal Anemia Syndrome

NCT05053893 ↗

Unknown 40 enrolled The Affiliated Hospital of Qingdao University
RandomizedParallel-groupOpen-labelTreatment

Summary

A randomized and parallel controlled trial design of comparing the new treatment group of Roxadustat combined with Sacubitril Valsartan Sodium Tablets with the traditional treatment group of recombinant human erythropoietin (EPO) combined with ACEI or ARB in Chinese patients with cardiorenal anemia syndrome.

Timeline

Start
2021-09-22
Primary completion
2022-07-01
Completion
2022-09-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Roxadustat Small molecule 100 mg Oral
Subject Roxadustat Small molecule 120 mg Oral
Subject Sacubitril-Valsartan Unknown 50 mg Oral
Subject epoetin alfa Protein / enzyme biologic 10000 iu Subcutaneous

Indications

cardio-renal syndrome